Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
暂无分享,去创建一个
Sally Hunsberger | R. Gray | R. Gelber | C. Hudis | J. Costantino | W. Barlow | J. Sparano | K. Pritchard | J. Zujewski | R. Enos | S. Hunsberger | Rebecca A Enos | Kathleen I Pritchard | William E Barlow | Joseph A Sparano | Richard D Gelber | Joseph P Costantino | J. Chapman | Clifford A Hudis | Robert J Gray | Judith-Anne W Chapman | Jo Anne Zujewski | J. W. Chapman
[1] P. Lønning,et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer* , 2004, The New England journal of medicine.
[2] Michael Gnant,et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial , 2005, The Lancet.
[3] E. Perez,et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. , 2004, The New England journal of medicine.
[4] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[5] J. Forbes,et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.
[6] C. Davies. Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen. , 2004, Cancer treatment reviews.
[7] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .